Sirolimus
Acute Biphenotypic Leukemia
Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05805605CT.gov Allo HSCT Using RIC and PTCy for Hematological Diseases | — | Recruiting | — | — | — |
NCT05170828CT.gov Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Biphenotypic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sirolimus (this asset) | Masonic Cancer Center, University of Minnesota | P2 | B · 60 |
| Fludarabine | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P2/3 | BB |
| Cytarabine | University of Washington | P2 | BB |
| Nivestim | Ossium Health, Inc. | P2 | BB |
| Busulfanum | Ossium Health, Inc. | P2 | BB |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | BB |
| Cyclophosphamide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
| Cladribine | University of Washington | P2 | BB |
| Sorafenib | University of Washington | P2 | BB |
+42 more in the Acute Biphenotypic Leukemia cohort
Other indications for Sirolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 73 |
| Disease Related To Transplantation | — | P4 | BBB · 72 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Sirolimus in Acute Biphenotypic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/sirolimus-acute-biphenotypic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →